Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Resource Type
Authors
Zingg D; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Bhin J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Yemelyanenko J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Kas SM; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Rolfs F; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; OncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Lutz C; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Lee JK; Foundation Medicine, Cambridge, MA, USA.; Klarenbeek S; Experimental Animal Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Silverman IM; Incyte Research Institute, Wilmington, DE, USA.; Annunziato S; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Chan CS; Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Medicine and Pharmacology, Rutgers University, Piscataway, NJ, USA.; Piersma SR; OncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Eijkman T; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Badoux M; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Gogola E; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Siteur B; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Sprengers J; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.; de Klein B; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; de Goeij-de Haas RR; OncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Riedlinger GM; Department of Medicine and Pharmacology, Rutgers University, Piscataway, NJ, USA.; Department of Pathology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Ke H; Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Medicine and Pharmacology, Rutgers University, Piscataway, NJ, USA.; Madison R; Foundation Medicine, Cambridge, MA, USA.; Drenth AP; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; van der Burg E; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Schut E; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Henneman L; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.; van Miltenburg MH; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Proost N; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Zhen H; Incyte, Wilmington, DE, USA.; Wientjens E; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; de Bruijn R; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.; de Ruiter JR; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Boon U; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; de Korte-Grimmerink R; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.; van Gerwen B; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Féliz L; Incyte Biosciences International, Morges, Switzerland.; Abou-Alfa GK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA.; Ross JS; Foundation Medicine, Cambridge, MA, USA.; Upstate University Hospital, Upstate Medical University, Syracuse, NY, USA.; van de Ven M; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Rottenberg S; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.; Bern Center for Precision Medicine, University of Bern, Bern, Switzerland.; Cuppen E; Oncode Institute, Utrecht, The Netherlands.; Hartwig Medical Foundation, Amsterdam, The Netherlands.; Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.; Chessex AV; Debiopharm International, Lausanne, Switzerland.; Ali SM; Foundation Medicine, Cambridge, MA, USA.; Burn TC; Incyte Research Institute, Wilmington, DE, USA.; Jimenez CR; OncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.; Ganesan S; Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. ganesash@cinj.rutgers.edu.; Department of Medicine and Pharmacology, Rutgers University, Piscataway, NJ, USA. ganesash@cinj.rutgers.edu.; Wessels LFA; Oncode Institute, Utrecht, The Netherlands. l.wessels@nki.nl.; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands. l.wessels@nki.nl.; Jonkers J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. j.jonkers@nki.nl.; Oncode Institute, Utrecht, The Netherlands. j.jonkers@nki.nl.
Source
Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: PubMed not MEDLINE; MEDLINE